1. Short- and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for patients with multiple primarily unresectable colorectal liver metastases: a propensity matching analysis
- Author
-
Baocai Xing, Kun Wang, Ming Liu, Yan-Yan Wang, Hongwei Wang, Kemin Jin, Wei Liu, and Quan Bao
- Subjects
medicine.medical_specialty ,Radiofrequency ablation ,medicine.medical_treatment ,Gastroenterology ,law.invention ,law ,Internal medicine ,Recurrence free survival ,medicine ,Long term outcomes ,Hepatectomy ,Humans ,In patient ,Major complication ,Progression-free survival ,Retrospective Studies ,Radiofrequency Ablation ,Hepatology ,business.industry ,Liver Neoplasms ,Treatment Outcome ,Propensity score matching ,Catheter Ablation ,Colorectal Neoplasms ,business - Abstract
Background Hepatectomy combined with intraoperative radiofrequency ablation (IORFA) is a strategy to eliminate all tumors in patients with multiple colorectal liver metastases (CRLM). This study aimed to evaluate the surgical and oncological outcomes of hepatectomy + IORFA for multiple unresectable CRLM. Methods We included patients who underwent combined hepatectomy and IORFA for multiple unresectable CRLM (n = 67) or hepatectomy alone (n = 268) for CRLM. Patients were matched in a 1:1 propensity score analysis to compare the short- and long-term outcomes between groups. Results Patients in hepatectomy + IORFA group had a median number of 10 liver lesions. Postoperative morbidity and the rate of major complications was similar between groups (P = 0.362, P = 1.000). The median overall survival (OS), progression free survival (PFS) and hepatic recurrence free survival (HRFS) was similar between groups (3-year OS: 54.2% versus 60.9%, P = 0.389; 3-year PFS: 7.9% versus 19.6%, P = 0.148; 3-year HRFS: 16.7% versus 31.5%, P = 0.202). Re-hepatectomy or radiofrequency ablation was used to treat 47.5% of hepatic recurrences, and the median OS was significantly higher than for patients treated with systemic treatment alone (P Conclusions Combining hepatectomy and IORFA could provide comparable survival rates for patients with multiple unresectable CRLM compared to those with resectable CRLM treated with hepatectomy alone.
- Published
- 2021